ID   AK1C1_HUMAN             Reviewed;         323 AA.
AC   Q04828; P52896; Q5SR15; Q7M4N2; Q9UCX2;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   15-MAR-2017, entry version 183.
DE   RecName: Full=Aldo-keto reductase family 1 member C1;
DE            EC=1.1.1.-;
DE   AltName: Full=20-alpha-hydroxysteroid dehydrogenase;
DE            Short=20-alpha-HSD;
DE            EC=1.1.1.149 {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
DE   AltName: Full=Chlordecone reductase homolog HAKRC;
DE   AltName: Full=Dihydrodiol dehydrogenase 1/2;
DE            Short=DD1/DD2;
DE   AltName: Full=High-affinity hepatic bile acid-binding protein;
DE            Short=HBAB;
DE   AltName: Full=Indanol dehydrogenase;
DE            EC=1.1.1.112 {ECO:0000269|PubMed:8573067};
DE   AltName: Full=Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase;
DE            EC=1.3.1.20 {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
GN   Name=AKR1C1; Synonyms=DDH, DDH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8486699;
RA   Stolz A., Hammond L., Lou H., Takikawa H., Ronk M., Shively J.E.;
RT   "cDNA cloning and expression of the human hepatic bile acid-binding
RT   protein. A member of the monomeric reductase gene family.";
RL   J. Biol. Chem. 268:10448-10457(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8132567;
RA   Lou H., Hammond L., Sharma V., Sparkes R.S., Lusis A.J., Stolz A.;
RT   "Genomic organization and chromosomal localization of a novel human
RT   hepatic dihydrodiol dehydrogenase with high affinity bile acid
RT   binding.";
RL   J. Biol. Chem. 269:8416-8422(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon;
RX   PubMed=7515059;
RA   Ciaccio P.J., Jaiswal A.K., Tew K.D.;
RT   "Regulation of human dihydrodiol dehydrogenase by Michael acceptor
RT   xenobiotics.";
RL   J. Biol. Chem. 269:15558-15562(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=7626489; DOI=10.1016/0960-0760(95)00019-V;
RA   Khanna M., Qin K.-N., Cheng K.-C.;
RT   "Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and
RT   molecular cloning of multiple cDNAs encoding structurally related
RT   proteins in humans.";
RL   J. Steroid Biochem. Mol. Biol. 53:41-46(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=10672042; DOI=10.1046/j.1365-2443.2000.00310.x;
RA   Nishizawa M., Nakajima T., Yasuda K., Kanzaki H., Sasaguri Y.,
RA   Watanabe K., Ito S.;
RT   "Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with
RT   three aldo-keto reductase genes.";
RL   Genes Cells 5:111-125(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Skin fibroblast;
RX   PubMed=11013348; DOI=10.1677/jme.0.0250221;
RA   Zhang Y., Dufort I., Rheault P., Luu-The V.;
RT   "Characterization of a human 20alpha-hydroxysteroid dehydrogenase.";
RL   J. Mol. Endocrinol. 25:221-228(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-323.
RC   TISSUE=Liver;
RX   PubMed=8274401; DOI=10.1016/0960-0760(93)90308-J;
RA   Qin K.-N., New M.I., Cheng K.-C.;
RT   "Molecular cloning of multiple cDNAs encoding human enzymes
RT   structurally related to 3 alpha-hydroxysteroid dehydrogenase.";
RL   J. Steroid Biochem. Mol. Biol. 46:673-679(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 10-31; 40-61; 69-126; 137-153; 162-206; 209-230;
RP   250-267; 271-289 AND 295-323, FUNCTION, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8573067; DOI=10.1042/bj3130373;
RA   Hara A., Matsuura K., Tamada Y., Sato K., Miyabe Y., Deyashiki Y.,
RA   Ishida N.;
RT   "Relationship of human liver dihydrodiol dehydrogenases to hepatic
RT   bile-acid-binding protein and an oxidoreductase of human colon
RT   cells.";
RL   Biochem. J. 313:373-376(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 18-323, AND PROTEIN SEQUENCE OF 18-31;
RP   105-131; 176-193 AND 271-294.
RC   TISSUE=Liver;
RX   PubMed=8172617; DOI=10.1042/bj2990545;
RA   Deyashiki Y., Ogasawara A., Nakayama T., Nakanishi M., Miyabe Y.,
RA   Sato K., Hara A.;
RT   "Molecular cloning of two human liver 3 alpha-
RT   hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical
RT   with chlordecone reductase and bile-acid binder.";
RL   Biochem. J. 299:545-552(1994).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   20ALPHA-HYDROXY-PROGESTERONE, AND MUTAGENESIS OF GLU-127; HIS-222;
RP   ARG-304; TYR-305; THR-307 AND ASP-309.
RX   PubMed=12899831; DOI=10.1016/S0022-2836(03)00762-9;
RA   Couture J.-F., Legrand P., Cantin L., Luu-The V., Labrie F.,
RA   Breton R.;
RT   "Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and
RT   site-directed mutagenesis studies lead to the identification of an
RT   alternative binding site for C21-steroids.";
RL   J. Mol. Biol. 331:593-604(2003).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   3-CHLORO-5-PHENYLSALICYLIC ACID.
RX   PubMed=21414777; DOI=10.1016/j.bmcl.2011.01.076;
RA   El-Kabbani O., Dhagat U., Soda M., Endo S., Matsunaga T., Hara A.;
RT   "Probing the inhibitor selectivity pocket of human 20alpha-
RT   hydroxysteroid dehydrogenase (AKR1C1) with X-ray crystallography and
RT   site-directed mutagenesis.";
RL   Bioorg. Med. Chem. Lett. 21:2564-2567(2011).
CC   -!- FUNCTION: Converts progesterone to its inactive form, 20-alpha-
CC       dihydroxyprogesterone (20-alpha-OHP). In the liver and intestine,
CC       may have a role in the transport of bile. May have a role in
CC       monitoring the intrahepatic bile acid concentration. Has a low
CC       bile-binding ability. May play a role in myelin formation.
CC       {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067}.
CC   -!- CATALYTIC ACTIVITY: 17-alpha,20-alpha-dihydroxypregn-4-en-3-one +
CC       NAD(P)(+) = 17-alpha-hydroxyprogesterone + NAD(P)H.
CC       {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067}.
CC   -!- CATALYTIC ACTIVITY: Trans-1,2-dihydrobenzene-1,2-diol + NADP(+) =
CC       catechol + NADPH. {ECO:0000269|PubMed:11013348,
CC       ECO:0000269|PubMed:8573067}.
CC   -!- CATALYTIC ACTIVITY: Indan-1-ol + NAD(P)(+) = indanone + NAD(P)H.
CC       {ECO:0000269|PubMed:8573067}.
CC   -!- ENZYME REGULATION: Inhibited by hexestrol with an IC(50) of 9.5
CC       uM, 1,10-phenanthroline with an IC(50) of 55 uM, 1,7-
CC       phenanthroline with an IC(50) of 72 uM, flufenamic acid with an
CC       IC(50) of 6.0 uM, indomethacin with an IC(50) of 140 uM, ibuprofen
CC       with an IC(50) of 950 uM, lithocholic acid with an IC(50) of 25
CC       uM, ursodeoxycholic acid with an IC(50) of 340 uM and
CC       chenodeoxycholic acid with an IC(50) of 570 uM.
CC       {ECO:0000269|PubMed:8573067}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5 uM for (s)-tetralol {ECO:0000269|PubMed:11013348,
CC         ECO:0000269|PubMed:8573067};
CC         KM=38 uM for (s)-indan-1-ol {ECO:0000269|PubMed:11013348,
CC         ECO:0000269|PubMed:8573067};
CC         KM=580 uM for benzene dihydrodiol {ECO:0000269|PubMed:11013348,
CC         ECO:0000269|PubMed:8573067};
CC         KM=3 uM for 5-beta-pregnane-3-alpha,20-alpha-diol
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=3 uM for 5-beta-pregnan-20-alpha-ol-3-one
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=12 uM for 4-pregnen-20-alpha-ol-3-one
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=133 uM for 9-alpha,11-beta-prostaglandin F(2)
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=2 uM for 5-beta-pregnan-3-alpha-ol-20-one
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=1 uM for 5-beta-androstane-3,17-dione
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC         KM=12 uM for prostaglandin D(2) {ECO:0000269|PubMed:11013348,
CC         ECO:0000269|PubMed:8573067};
CC         KM=0.6 uM for 20-alpha-hydroxyprogesterone (with NADH)
CC         {ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:8573067};
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:12899831,
CC       ECO:0000269|PubMed:21414777}.
CC   -!- INTERACTION:
CC       P26045:PTPN3; NbExp=5; IntAct=EBI-2116455, EBI-1047946;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested including
CC       liver, prostate, testis, adrenal gland, brain, uterus, mammary
CC       gland and keratinocytes. Highest levels found in liver, mammary
CC       gland and brain. {ECO:0000269|PubMed:11013348}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M86609; AAB02880.1; -; mRNA.
DR   EMBL; U05861; AAA18115.1; -; Genomic_DNA.
DR   EMBL; U05853; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05854; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05855; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05857; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05858; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05859; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05860; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05684; AAA16227.1; -; mRNA.
DR   EMBL; AB031083; BAA92883.1; -; mRNA.
DR   EMBL; AB032150; BAA92886.1; -; Genomic_DNA.
DR   EMBL; BT007197; AAP35861.1; -; mRNA.
DR   EMBL; AL713867; CAI16409.1; -; Genomic_DNA.
DR   EMBL; AC091817; CAI16409.1; JOINED; Genomic_DNA.
DR   EMBL; BC015490; AAH15490.1; -; mRNA.
DR   EMBL; BC020216; AAH20216.1; -; mRNA.
DR   EMBL; BC040210; AAH40210.1; -; mRNA.
DR   EMBL; S68290; AAD14012.1; -; mRNA.
DR   EMBL; D26124; BAA05121.1; -; mRNA.
DR   CCDS; CCDS7061.1; -.
DR   PIR; A53436; A53436.
DR   PIR; I73675; I73675.
DR   PIR; S59619; S59619.
DR   PIR; S61515; S61515.
DR   RefSeq; NP_001344.2; NM_001353.5.
DR   UniGene; Hs.460260; -.
DR   PDB; 1MRQ; X-ray; 1.59 A; A=2-323.
DR   PDB; 3C3U; X-ray; 1.80 A; A=1-323.
DR   PDB; 3GUG; X-ray; 1.90 A; A=1-323.
DR   PDB; 3NTY; X-ray; 1.87 A; A=1-323.
DR   PDB; 4YVP; X-ray; 2.60 A; A/B=1-323.
DR   PDBsum; 1MRQ; -.
DR   PDBsum; 3C3U; -.
DR   PDBsum; 3GUG; -.
DR   PDBsum; 3NTY; -.
DR   PDBsum; 4YVP; -.
DR   ProteinModelPortal; Q04828; -.
DR   SMR; Q04828; -.
DR   BioGrid; 108012; 8.
DR   IntAct; Q04828; 4.
DR   MINT; MINT-5001209; -.
DR   STRING; 9606.ENSP00000370254; -.
DR   BindingDB; Q04828; -.
DR   ChEMBL; CHEMBL5905; -.
DR   DrugBank; DB03461; 2'-Monophosphoadenosine 5'-Diphosphoribose.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB07931; Hexestrol.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00936; Salicylic acid.
DR   SwissLipids; SLP:000000802; -.
DR   iPTMnet; Q04828; -.
DR   PhosphoSitePlus; Q04828; -.
DR   SwissPalm; Q04828; -.
DR   BioMuta; AKR1C1; -.
DR   DMDM; 416877; -.
DR   EPD; Q04828; -.
DR   MaxQB; Q04828; -.
DR   PaxDb; Q04828; -.
DR   PeptideAtlas; Q04828; -.
DR   PRIDE; Q04828; -.
DR   DNASU; 1645; -.
DR   Ensembl; ENST00000380872; ENSP00000370254; ENSG00000187134.
DR   GeneID; 1645; -.
DR   KEGG; hsa:1645; -.
DR   UCSC; uc001ihq.4; human.
DR   CTD; 1645; -.
DR   DisGeNET; 1645; -.
DR   GeneCards; AKR1C1; -.
DR   HGNC; HGNC:384; AKR1C1.
DR   HPA; CAB047303; -.
DR   HPA; HPA068265; -.
DR   MalaCards; AKR1C1; -.
DR   MIM; 600449; gene.
DR   neXtProt; NX_Q04828; -.
DR   OpenTargets; ENSG00000187134; -.
DR   PharmGKB; PA24677; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   eggNOG; COG0656; LUCA.
DR   GeneTree; ENSGT00760000119041; -.
DR   HOGENOM; HOG000250272; -.
DR   HOVERGEN; HBG000020; -.
DR   InParanoid; Q04828; -.
DR   KO; K00212; -.
DR   PhylomeDB; Q04828; -.
DR   TreeFam; TF106492; -.
DR   BioCyc; MetaCyc:HS10741-MONOMER; -.
DR   BRENDA; 1.1.1.149; 2681.
DR   BRENDA; 1.1.1.270; 2681.
DR   BRENDA; 1.1.1.50; 2681.
DR   BRENDA; 1.3.1.20; 2681.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   SABIO-RK; Q04828; -.
DR   SIGNOR; Q04828; -.
DR   EvolutionaryTrace; Q04828; -.
DR   GeneWiki; AKR1C1; -.
DR   GenomeRNAi; 1645; -.
DR   PRO; PR:Q04828; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000187134; -.
DR   CleanEx; HS_AKR1C1; -.
DR   ExpressionAtlas; Q04828; baseline and differential.
DR   Genevisible; Q04828; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0047006; F:17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004032; F:alditol:NADP+ 1-oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0004033; F:aldo-keto reductase (NADP) activity; TAS:UniProtKB.
DR   GO; GO:0047042; F:androsterone dehydrogenase (B-specific) activity; IDA:UniProtKB.
DR   GO; GO:0032052; F:bile acid binding; IDA:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IDA:UniProtKB.
DR   GO; GO:0047718; F:indanol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0016655; F:oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor; IDA:UniProtKB.
DR   GO; GO:0018636; F:phenanthrene 9,10-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0047115; F:trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:UniProtKB.
DR   GO; GO:0008206; P:bile acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0071395; P:cellular response to jasmonic acid stimulus; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; TAS:UniProtKB.
DR   GO; GO:0044597; P:daunorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0007586; P:digestion; IDA:UniProtKB.
DR   GO; GO:0044598; P:doxorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030299; P:intestinal cholesterol absorption; TAS:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IDA:UniProtKB.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0046683; P:response to organophosphorus; IEP:UniProtKB.
DR   GO; GO:0042574; P:retinal metabolic process; IDA:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0006805; P:xenobiotic metabolic process; NAS:UniProtKB.
DR   CDD; cd06660; Aldo_ket_red; 1.
DR   Gene3D; 3.20.20.100; -; 1.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR020471; Aldo/keto_reductase.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   PANTHER; PTHR11732; PTHR11732; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; SSF51430; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Direct protein sequencing;
KW   NADP; Oxidoreductase; Polymorphism; Reference proteome.
FT   CHAIN         1    323       Aldo-keto reductase family 1 member C1.
FT                                /FTId=PRO_0000124633.
FT   NP_BIND      20     24       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   NP_BIND     166    167       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   NP_BIND     216    222       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   NP_BIND     270    280       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   ACT_SITE     55     55       Proton donor. {ECO:0000250}.
FT   BINDING      24     24       Substrate.
FT   BINDING      50     50       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   BINDING     117    117       Substrate. {ECO:0000250}.
FT   BINDING     190    190       NADP. {ECO:0000269|PubMed:12899831,
FT                                ECO:0000269|PubMed:21414777}.
FT   BINDING     222    222       Substrate.
FT   BINDING     227    227       Substrate.
FT   SITE         54     54       Important for substrate specificity.
FT                                {ECO:0000250}.
FT   SITE         84     84       Lowers pKa of active site Tyr.
FT                                {ECO:0000250}.
FT   SITE        222    222       May be involved in the mediating step
FT                                between the transformation of
FT                                progesterone and the release of the
FT                                cofactor.
FT   VARIANT     170    170       R -> H (in dbSNP:rs139588200).
FT                                /FTId=VAR_048214.
FT   VARIANT     172    172       Q -> L (in dbSNP:rs17354444).
FT                                /FTId=VAR_048215.
FT   MUTAGEN     127    127       E->D: 30-fold decrease in k(cat)/K(m)
FT                                value for progesterone reduction; no
FT                                effect on the K(m) value.
FT                                {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     222    222       H->I: Marked decrease in k(cat)/K(m)
FT                                value for progesterone; 24-fold decrease
FT                                for progesterone reduction; 18-fold
FT                                decrease for 20alpha-OHProg oxidation.
FT                                95-fold decrease in K(m) value for NADPH.
FT                                {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     222    222       H->S: Marked decrease in k(cat)/K(m)
FT                                value for progesterone; 10-fold decrease
FT                                for progesterone reduction; 3-fold
FT                                decrease for 20alpha-OHProg oxidation.
FT                                10-fold decrease in K(m) value for NADPH.
FT                                {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     304    304       R->L: 70-fold decrease in progesterone
FT                                reduction. No effect on DHT reduction.
FT                                {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     305    305       Y->F: No effect on progesterone
FT                                reduction. {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     307    307       T->V: No effect on progesterone
FT                                reduction. {ECO:0000269|PubMed:12899831}.
FT   MUTAGEN     309    309       D->V: No effect on progesterone
FT                                reduction. {ECO:0000269|PubMed:12899831}.
FT   CONFLICT      3      3       S -> A (in Ref. 4; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT     95     95       V -> D (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   CONFLICT    158    158       G -> E (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   CONFLICT    171    172       RQ -> ST (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   CONFLICT    183    184       KY -> QV (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   CONFLICT    222    222       H -> L (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   CONFLICT    319    319       F -> I (in Ref. 4; no nucleotide entry
FT                                and 10; AAD14012). {ECO:0000305}.
FT   STRAND        7      9       {ECO:0000244|PDB:1MRQ}.
FT   STRAND       15     22       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        33     44       {ECO:0000244|PDB:1MRQ}.
FT   STRAND       48     50       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        53     55       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        58     70       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        76     78       {ECO:0000244|PDB:1MRQ}.
FT   STRAND       80     85       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        87     89       {ECO:0000244|PDB:1MRQ}.
FT   HELIX        92    106       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      111    116       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      124    126       {ECO:0000244|PDB:3C3U}.
FT   STRAND      133    135       {ECO:0000244|PDB:4YVP}.
FT   HELIX       144    156       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      159    167       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       170    177       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      187    192       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      194    197       {ECO:0000244|PDB:3GUG}.
FT   HELIX       200    208       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      212    217       {ECO:0000244|PDB:1MRQ}.
FT   TURN        225    227       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       235    237       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       239    248       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       252    262       {ECO:0000244|PDB:1MRQ}.
FT   STRAND      266    270       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       274    280       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       281    285       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       290    297       {ECO:0000244|PDB:1MRQ}.
FT   HELIX       309    311       {ECO:0000244|PDB:1MRQ}.
SQ   SEQUENCE   323 AA;  36788 MW;  9CB215478FBD29D5 CRC64;
     MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEATKL AIEAGFRHID SAHLYNNEEQ
     VGLAIRSKIA DGSVKREDIF YTSKLWCNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV
     SVKPGEEVIP KDENGKILFD TVDLCATWEA VEKCKDAGLA KSIGVSNFNR RQLEMILNKP
     GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV
     LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN
     RNVRYLTLDI FAGPPNYPFS DEY
//
